Structure−Activity Relationships for a Novel Series of Pyrido[2,3-<i>d</i>]pyrimidine Tyrosine Kinase Inhibitors
作者:James M. Hamby、Cleo J. C. Connolly、Mel C. Schroeder、R. Thomas Winters、H. D. Hollis Showalter、Robert L. Panek、Terry C. Major、Bronislawa Olsewski、Michael J. Ryan、Tawny Dahring、Gina H. Lu、Joan Keiser、Aneesa Amar、Cindy Shen、Alan J. Kraker、Veronika Slintak、James M. Nelson、David W. Fry、Laura Bradford、Hussein Hallak、Annette M. Doherty
DOI:10.1021/jm970367n
日期:1997.7.1
receptor tyrosine kinases led to the development of a novel series of ATP competitive pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. The initial lead, 1-[2-amino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-3- tert-butylurea (4b, PD-089828), was found to be a broadly active tyrosine kinase inhibitor. Compound 4b inhibited the PDGFr, FGFr, EGFr, and c-src tyrosine kinases with IC50 values
化合物库中成纤维细胞生长因子(FGFr)和血小板衍生生长因子(PDGFr)受体酪氨酸激酶抑制剂的筛选导致了一系列新型的ATP竞争性吡啶并[2,3-d]嘧啶酪氨酸激酶抑制剂。发现了最初的铅1- [2-氨基-6-(2,6-二氯苯基)吡啶基[2,3-d]嘧啶-7-基] -3-叔丁基脲(4b,PD-089828)成为广泛活性的酪氨酸激酶抑制剂。化合物4b抑制PDGFr,FGFr,EGFr和c-src酪氨酸激酶,IC50值分别为1.11、0.13、0.45和0.22 microM。随后的SAR研究导致合成了新的类似物,相对于最初的铅,这些类似物的效能,溶解度和生物利用度均得到了改善。例如,将[4-(二乙基氨基)丁基]氨基侧链引入4b的2-位得到具有增强的效能和生物利用度的化合物6c。化合物6c抑制PDGF刺激的血管平滑肌细胞增殖,IC50为0.3 microM。此外,用6-(3',5'-二甲氧基苯基)官能团代替4b的6-(2